Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
48.04 USD | -1.15% | -1.66% | +1.74% |
May. 07 | Loop Capital Adjusts Price Target on Ingevity to $56 From $49, Maintains Hold Rating | MT |
May. 02 | Transcript : Ingevity Corporation, Q1 2024 Earnings Call, May 02, 2024 |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- One of the major weak points of the company is its financial situation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Diversified Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.74% | 1.75B | B- | ||
+3.28% | 77.85B | B | ||
-4.06% | 45.15B | A- | ||
+4.00% | 33.45B | C | ||
+15.05% | 19.03B | B | ||
+15.01% | 12.15B | A- | ||
-1.50% | 10.56B | - | ||
-21.68% | 10.17B | B | ||
-1.30% | 9.08B | A- | ||
-6.85% | 8.2B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NGVT Stock
- Ratings Ingevity Corporation